Amneal Pharmaceuticals (AMRX) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

AMRX · Stock Price

USD 13.72+6.31 (+85.16%)

Market Cap: $4.3B

Historical price data

Market Cap: $4.3BPipeline: 14 drugs (9 Phase 3)Patents: 20Founded: 2002Employees: ~2,500 (U.S.)HQ: Bridgewater, United States

Overview

Amneal Pharmaceuticals, founded in 2002 and publicly traded (NYSE: AMRX), has evolved from a generic drug company into a diversified biopharmaceutical enterprise with a mission to make medicine accessible for all. Its strategy is built on a three-pillar portfolio of complex generics, biosimilars, and specialty injectables, supported by significant U.S. manufacturing reinvestment. Recent high-profile launches like Brekiya for migraine and CREXONT for Parkinson's disease demonstrate its capability to develop and commercialize advanced, difficult-to-formulate products that address unmet patient needs and generate sustainable growth.

OncologyCentral Nervous SystemGastroenterologyEmergency/Critical CareHematologyOphthalmologyPsychiatry

Technology Platform

Integrated capabilities in advanced formulation science, complex generic and biosimilar development, and high-quality, at-scale manufacturing, particularly for sterile injectables and controlled-release dosage forms.

Pipeline

14

14 drugs in pipeline9 in Phase 3

Drug	Indication	Stage
CREXONT ER	Parkinson Disease	Approved
CREXONT ER	Parkinson Disease	Approved
Testosterone Topical Gel, 1.62% Metered Pump + AndroGel (tes...	Primary Hypogonadism	Phase 3
Diclofenac Sodium Topical Gel, 1% + Voltaren Topical Gel, 1%...	Osteoarthritis	Phase 3
Phenazopyridine Hydrochloride + Placebo	Pain	Phase 3